BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25869338)

  • 21. Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer.
    Lavrenkov K; Partridge M; Cook G; Brada M
    Radiother Oncol; 2005 Oct; 77(1):1-4. PubMed ID: 16225943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation?
    Rodríguez N; Sanz X; Trampal C; Foro P; Reig A; Lacruz M; Membrive I; Lozano J; Quera J; Algara M
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):659-66. PubMed ID: 20133071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study.
    Kolodziejczyk M; Kepka L; Dziuk M; Zawadzka A; Szalus N; Gizewska A; Bujko K
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1008-14. PubMed ID: 20656419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data.
    Mac Manus MP; Everitt S; Bayne M; Ball D; Plumridge N; Binns D; Herschtal A; Cruickshank D; Bressel M; Hicks RJ
    Radiother Oncol; 2013 Mar; 106(3):292-8. PubMed ID: 23541364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
    Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
    Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning.
    Fleckenstein J; Kremp K; Kremp S; Palm J; Rübe C
    Strahlenther Onkol; 2016 Feb; 192(2):75-82. PubMed ID: 26438071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
    Yap ML; Sun A; Higgins J; Clarke K; Marshall A; Becker N; Le LW; Vines DC; Bezjak A; Bissonnette JP
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e199-e205. PubMed ID: 27637725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy--a retrospective study.
    Abramyuk A; Appold S; Zöphel K; Hietschold V; Baumann M; Abolmaali N
    Lung Cancer; 2012 Nov; 78(2):148-52. PubMed ID: 22922126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical review of PET-CT for radiotherapy planning in lung cancer.
    Senan S; De Ruysscher D
    Crit Rev Oncol Hematol; 2005 Dec; 56(3):345-51. PubMed ID: 15990331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer.
    Pfannenberg AC; Aschoff P; Brechtel K; Müller M; Bares R; Paulsen F; Scheiderbauer J; Friedel G; Claussen CD; Eschmann SM
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):36-44. PubMed ID: 16896664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The use of PET/CT in radiotherapy of patients with non-small cell lung cancer].
    Lõcsei Z; Hideghéty K; Farkas R; Bellyei S; Sárosi V; Sebestyén K; Sebestyén Z; Kovács P; Mangel L
    Magy Onkol; 2011 Nov; 55(4):274-80. PubMed ID: 22128310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET scans in radiotherapy planning of lung cancer.
    De Ruysscher D; Nestle U; Jeraj R; Macmanus M
    Lung Cancer; 2012 Feb; 75(2):141-5. PubMed ID: 21920625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and staging impact of radiotherapy planning FDG-PET-CT in non-small-cell lung cancer.
    Lin P; Koh ES; Lin M; Vinod SK; Ho-Shon I; Yap J; Som S
    Radiother Oncol; 2011 Nov; 101(2):284-90. PubMed ID: 21777988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined PET/CT for IMRT treatment planning of NSCLC: contrast-enhanced CT images for Monte Carlo dose calculation.
    Mönnich D; Lächelt S; Beyer T; Werner MK; Thorwarth D
    Phys Med; 2013 Nov; 29(6):644-9. PubMed ID: 22975430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET and PET-CT in radiation treatment planning for lung cancer.
    Aristei C; Falcinelli L; Palumbo B; Tarducci R
    Expert Rev Anticancer Ther; 2010 Apr; 10(4):571-84. PubMed ID: 20397922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives.
    Nestle U; Kremp S; Grosu AL
    Radiother Oncol; 2006 Nov; 81(2):209-25. PubMed ID: 17064802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.
    Even AJG; Reymen B; La Fontaine MD; Das M; Jochems A; Mottaghy FM; Belderbos JSA; De Ruysscher D; Lambin P; van Elmpt W
    Acta Oncol; 2017 Nov; 56(11):1591-1596. PubMed ID: 28840770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.